Document:

EX-4.3

 Exhibit 4.3 

SONENDO, INC. 
 THIRD
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 
 This THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the
“Agreement”) is made as of October 26, 2018, by and among Sonendo, Inc., a Delaware corporation (the “Company”), and each of the persons listed on the attached Schedule A who become signatories to this
Agreement (collectively, the “Investors”). 
 R E C I T A L S 

A. The Company and certain of the Investors are parties to that certain Second Amended and Restated Investors’ Rights Agreement dated as
of July 20, 2017 (the “Prior Agreement”). 
 B. In connection with the purchase and sale of shares of Series E
Preferred Stock, par value $0.001 per share (the “Series E Preferred Stock”), of the Company pursuant to the terms of a Series E Preferred Stock Purchase Agreement dated October 26, 2018 by and among the Company and the
Investors (as defined therein) party thereto (as may be amended from time to time, the “Purchase Agreement”), the Company and the other parties to the Prior Agreement desire to amend and restate the Prior Agreement in its entirety.

 C. The obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement. 

THE PARTIES AGREE AS FOLLOWS: 

SECTION 1. CERTAIN DEFINITIONS. 
 As
used in this Agreement, the following terms shall have the following respective meanings: 
 (a) “Affiliate” shall mean with
respect to any Person, any Person which directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, including without limitation any general partner, managing member, officer or
director of such Person or any venture capital fund, private equity fund or other pooled investment vehicle now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company
with, such Person. For the avoidance of doubt, DNA 07 Limited and Timwell Corporation Limited shall be deemed Affiliates for purposes of this Agreement. 

(b) “Board” shall mean the Board of Directors of the Company. 

(c) “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the
Securities Act. 

 (d) “Convertible Securities” shall mean the Company’s Series A-1 Preferred Stock, par value $0.001 per share (“Series A-1 Preferred Stock”), Series B Preferred Stock, par value $0.001 per share (“Series B
Preferred Stock”), Series C Preferred Stock, par value $0.001 per share (“Series C Preferred Stock”), Series C-1 Preferred Stock, par value $0.001 per share (“Series C-1 Preferred Stock”), Series D Preferred Stock, par value $0.001 per share (“Series D Preferred Stock”), and Series E Preferred Stock, par value $0.001 per share (“Series E
Preferred Stock”). 
 (e) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any
similar federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 (f)
“Form S-3” shall mean Form S-3 issued by the Commission or any substantially similar form then in effect. 

(g) “Holder” shall mean any holder of outstanding Registrable Securities, but only if such holder is an Investor or an
assignee or transferee of Registrable Securities. 
 (h) “Initiating Holders” shall mean Holders who in the aggregate hold
at least a majority of the Registrable Securities. 
 (i) “Major Holder” shall mean an Investor or transferees of such
Investor who together with its Affiliates in the aggregate are Holders of not less than five percent (5%) of the combined voting power of the Preferred Stock. 

(j) “Material Adverse Event” shall mean an occurrence having a consequence that either (a) is materially adverse as to
the business, properties, prospects or financial condition of the Company or (b) is reasonably foreseeable, and if it were to occur might materially adversely affect the business, properties, prospects or financial condition of the Company.

 (k) “Person” shall mean an individual, a corporation, a partnership, a trust or unincorporated organization or any other
entity or organization. 
 (l) “Preferred Stock Directors” shall have the meaning set forth in the Restated Certificate.

 (m) “Qualified Public Offering” shall have the meaning set forth in the Restated Certificate. 

(n) The terms “Register”, “Registered” and “Registration” refer to a registration effected
by preparing and filing a registration statement in compliance with the Securities Act (“Registration Statement”), and the declaration or ordering of the effectiveness of such Registration Statement. 

(o) “Registrable Securities” shall mean (i) the Common Stock issuable or issued upon conversion of the Convertible
Securities; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; (iii) any
securities of the Company granted Registration rights pursuant to Section 3.7 of this Agreement and (iv) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or

  
 2 

 
other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in
all cases, however, any Registrable Securities sold or transferred by a Person in a transaction in which the applicable rights under this Agreement are not assigned, and excluding for purposes of any shares for which Registration rights have
terminated pursuant to Section 3.13 of this Agreement. 
 (p) “Registration Expenses” shall mean
all expenses incurred by the Company in complying with Sections 3.1 or 3.2 of this Agreement, including, without limitation, all federal and state registration, qualification and filing fees, printing expenses, fees and
disbursements of counsel for the Company and one (1) special counsel for the Holders selected by the Holders holding a majority of the Registrable Securities to be registered (if different from the Company), blue sky fees and expenses, and the
expense of any special audits incident to or required by any such Registration, but excludes underwriting discounts and commissions, stock transfer taxes and fees of any additional counsel to the selling stockholders, except as otherwise provided
herein. 
 (q) “Restated Certificate” shall mean the Company’s Amended and Restated Certificate of Incorporation (as
may be amended from time to time). 
 (r) “Securities Act” shall mean the Securities Act of 1933, as amended, or any
similar federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 (s)
“Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities pursuant to this Agreement. 

(t) “Voting Agreement” shall mean that certain Fourth Amended and Restated Voting Agreement, dated as of the date hereof, by
and among the Company, the Stockholders (as such term is used therein) and the Investors (as such term is used therein). 
 SECTION 2. COVENANTS OF
THE COMPANY 
 2.1 Financial Statements and Reports to Stockholders; Budget. 

The Company shall deliver to each Major Holder: 

(a) As soon as practicable after the end of each fiscal year of the Company, and in any event within one hundred eighty (180) days
thereafter, an audited consolidated balance sheet of the Company as of the end of such year and audited consolidated statements of income, stockholders’ equity and cash flows for such year, which year-end
financial reports shall be in reasonable detail and shall be accompanied by the opinion of independent public accountants of a nationally recognized standing selected by the Company. 

(b) As soon as practicable after the end of each month, and in any event within thirty (30) days thereafter, consolidated balance sheets
of the Company and its subsidiaries, if any, as of the end of each such month and consolidated statements of income and cash flows for such month and for the current fiscal year to date, all prepared in accordance with GAAP. 

  
 3 

 (c) As soon as practicable following submission to and approval by the Board, but in no
event later than the end of each fiscal year, a comprehensive operating budget forecasting the Company’s revenues, expenses, and cash position on a month-to-month
basis for the next fiscal year, and promptly after prepared, any other budgets or revised budgets prepared by the Company. 
 (d) Promptly
following the end of each fiscal quarter of the Company, an up-to-date capitalization table. 

(e) Contemporaneously with delivery to holders of Common Stock or other securities of the Company, a copy of each report of the Company that
the Company delivers to such holders of Common Stock or other securities of the Company. 
 2.2 Inspection. 

The Company shall permit each Major Holder, at such Major Holder’s expense, to visit and inspect the Company’s properties, to
examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by each such Major Holder; provided, however, that the Company shall not be
obligated pursuant to this Section 2.2 to provide any information which it reasonably considers upon advice of counsel to be a trade secret or confidential information. The rights of a Major Holder under this
Section 2.2 may not be assigned as part of such Major Holder’s sale of any of the Registrable Securities or Convertible Securities except with the consent of the Company, which consent shall not be unreasonably
withheld. 
 2.3 Confidentiality. 

Each Investor agrees and will cause any representative of the Investor to hold in confidence and trust and not use or disclose any information
provided to or learned by it in connection with its rights under this Section 2, except that such Investor may disclose such information to (i) to its attorneys, accountants, consultants, and other professionals to the
extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) any general partner, limited partner, member, subsidiary or parent (and their respective representatives) of such Investor for the
purpose of evaluating its investment in the Company as long as (a) such general partner, limited partner, member, subsidiary or parent is advised of the confidentiality provisions of this Section 2.3 and (b) such
Investor uses its commercially reasonable best efforts to ensure that such general partner, limited partner, member, subsidiary or parent holds such information in confidence and trust and will not use or disclose any information provided to or
learned by it except as required by law; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such
Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure
and takes reasonable steps to minimize the extent of any such required disclosure. Notwithstanding the foregoing or anything to the contrary herein, the Company acknowledges that the Investors may invest in, or have general knowledge with respect
to, the industry in which the Company operates and the topics generally covered in information provided by the Company (including, without limitation, any confidential information). Neither the execution of this Agreement nor receipt of Company
confidential information shall restrict or preclude such activities or use of such general knowledge. 

  
 4 

 2.4 Proprietary Information and Inventions Agreements. 

The Company agrees to require each officer, each current employee of the Company and each employee hired by the Company after the date hereof
to execute a non-disclosure and proprietary rights assignment agreement in a form reasonably acceptable to the each of the Preferred Stock Directors as a condition of employment or continued employment or
engagement, as the case may be, unless otherwise approved by the Board. 
 2.5 Non-Competition
and Non-Solicitation Agreements. 
 To the extent not prohibited by law, the Company agrees to
require each officer, each current employee of the Company and each employee hired by the Company after the date hereof to execute a one-year non-competition and non-solicitation agreements in a form reasonably acceptable to each of the Preferred Stock Directors as a condition of employment or continued employment or engagement, as the case may be, unless otherwise approved
by the Board. 
 2.6 Lock-Up and Drag Along Agreements. 

The Company agrees that, until the time of the Company’s initial public offering of Common Stock pursuant to a Registration Statement, in
the event that the Company enters into an agreement with any Person to issue shares of capital stock (or securities convertible or exercisable into shares of capital stock) to such Person, the Company agrees to include, as a condition to entering
into such agreement, a market standoff or “lockup” language substantially the same as Section 3.9. 

2.7 Voting Agreement. 

The Company agrees that, until the time of the Company’s initial public offering of Common Stock pursuant to a Registration Statement, in
the event that the Company (i) enters into an agreement with any Person to issue shares of capital stock to such Person, following which such Person shall hold Shares constituting one percent (1%) or more of the Company’s then outstanding
capital stock (treating for this purpose all shares of Common Stock issuable upon exercise of or conversion of outstanding options, warrants or convertible securities, as if exercised and/or converted or exchanged) or (ii) enters into an
agreement with any Person with respect to the grant of restricted stock or stock options, then the Company shall cause such Person, as a condition precedent to entering into such agreement, to become a party to the Voting Agreement. 

2.8 Insurance. 
 Unless
otherwise determined by the Board, the Company shall cause to be maintained a key man life insurance policy on Bjarne Bergheim in an amount designated by the Board, with the proceeds payable to the Company. The Company shall maintain directors’
and officers’ liability insurance (the “D & O Policy”) from financially sound and reputable insurers in an amount approved by the Board. 

  
 5 

 2.9 Additional Investment Opportunities. If General Atlantic (SOI), L.P.
(“General Atlantic”) purchases at least Ten Million Dollars ($10,000,000) of Series E Preferred Stock pursuant to the Purchase Agreement, then General Atlantic and the other “Investors” who purchased Series E Preferred
Stock pursuant to that certain Series E Preferred Stock Purchase Agreement dated July 20, 2017 by and among the Company, General Atlantic, and such other Investors (the “Other Existing Holders”) shall have the right to make
additional investments in the Company as follows: 
 (a) June 2019 and December 2019 Options. 

(i) June 2019 Option. 

(1) At any time between June 14, 2019 and September 14, 2019, the Company may elect to hold a closing (the “June 2019
Financing”) at which General Atlantic, and each of the Other Existing Holders that has not failed to purchase its commitment of Series E Preferred Stock under the Purchase Agreement (the “Eligible Holders”), shall have a
right, but not an obligation to invest in the Company an aggregate amount up to Seventeen Million Dollars ($17,000,000); provided that such amount shall be allocated (A) Thirteen Million Six Hundred Thousand Dollars ($13,600,000) to General
Atlantic and (B) Three Million Four Hundred Thousand Dollars ($3,400,000) to the Eligible Holders pro rata according to the respective amounts of Series E Preferred Stock owned by the Eligible Holders. If the Company elects to hold the June
2019 Financing, the Company shall give written notice to General Atlantic and the Eligible Holders at least twenty (20) days in advance of the consummation thereof (the “June 2019 Financing Notice”). General Atlantic and the
Eligible Holders shall exercise their investment right contemplated by this Section 2.9(a)(i)(1) (if at all) by giving written notice thereof (which such notice shall state the amount such Person elects to
invest) to the Company no later than fifteen (15) days following the date of delivery of the June 2019 Financing Notice. The June 2019 Financing contemplated by this Section 2.9(a)(i)(1) will only be held
if General Atlantic elects to exercise its investment right under this Section 2.9(a)(i)(1) and invests at least Ten Million Dollars ($10,000,000) in connection with the June 2019 Financing. The consummation
of the June 2019 Financing shall occur promptly after the date, if any, as General Atlantic elects to exercise its investment right contemplated by this Section 2.9(a)(i)(1); provided that the consummation of
the June 2019 Financing may be tolled to the extent necessary pending the receipt of any required regulatory or other governmental approvals. 

(2) In the event the Company does not elect to hold the June 2019 Financing, General Atlantic shall have a right, but not an obligation, to
elect, between September 16, 2019 and September 30, 2019 to hold the June 2019 Financing at which General Atlantic will invest an amount equal to at least Ten Million Dollars ($10,000,000) but not to exceed Thirteen Million Six Hundred
Thousand Dollars ($13,600,000), and the Eligible Holders shall have the right, but not the obligation, to invest up to Three Million Four Hundred Thousand Dollars ($3,400,000) pro rata according to the respective amounts of Series E Preferred Stock
owned by the Eligible Holders. The consummation of the June 2019 Financing contemplated by this Section 2.9(a)(i)(2) shall occur promptly after the date, if any, as General Atlantic elects to

  
 6 

 
hold the June 2019 Financing, but in no event later than October 15, 2019; provided that the consummation of the June 2019 Financing may be tolled to the extent necessary pending the receipt
of any required regulatory or other governmental approvals. Notwithstanding the foregoing, General Atlantic shall have no right to elect to hold the June 2019 Financing if the Company has filed a Form S-1
Registration Statement for a firmly underwritten public offering of the Company’s Common Stock; provided that if the Company does not consummate such public offering within three (3) months of the filing of such registration statement,
General Atlantic shall again have the right to elect, within fourteen (14) days after the expiration of such three- (3-) month period, to hold the June 2019 Financing in accordance with this
Section 2.9(a)(i)(2). 
 (ii) December 2019 Option. 

(1) At any time between December 2, 2019 and March 4, 2020, the Company may elect to hold a closing (the “December 2019
Financing”) at which General Atlantic and each of the Eligible Holders shall have a right, but not an obligation, to invest in the Company an aggregate amount up to Twenty-Two Million Five Hundred
Thousand Dollars ($22,500,000); provided that such amount shall be allocated (A) Eighteen Million Dollars ($18,000,000) to General Atlantic and (B) Four Million Five Hundred Thousand Dollars ($4,500,000) to the Eligible Holders pro rata
according to the respective amounts of Series E Preferred Stock owned by the Eligible Holders. If the Company elects to hold the December 2019 Financing, the Company shall give written notice to General Atlantic and the Eligible Holders at least
twenty (20) days in advance of the consummation thereof (the “December 2019 Financing Notice”). General Atlantic and the Eligible Holders shall exercise their investment right contemplated by this
Section 2.9(a)(ii)(1) (if at all) by giving written notice thereof (which such notice shall state the amount such Person elects to invest) to the Company no later than fifteen (15) days following the date of delivery
of the December 2019 Financing Notice. The December 2019 Financing contemplated by this Section 2.9(a)(ii)(1) will only be held if General Atlantic elects to exercise its investment right contemplated by this
Section 2.9(a)(ii)(1) and invests at least Ten Million Dollars ($10,000,000) in connection with the December 2019 Financing. The consummation of the December 2019 Financing shall occur promptly after the date, if any, as
General Atlantic elects to exercise its investment right contemplated by this Section 2.9(a)(ii)(1); provided that the consummation of the December 2019 Financing may be tolled to the extent necessary pending the receipt of
any required regulatory or other governmental approvals. 
 (2) In the event the Company does not elect to hold the December 2019
Financing, General Atlantic shall have a right, but not an obligation, to elect, between March 5, 2020 and March 19, 2020, to hold the December 2019 Financing at which General Atlantic will invest an amount equal to at least Ten Million
Dollars ($10,000,000) but not to exceed Eighteen Million Dollars ($18,000,000), and the Eligible Holders shall have the right, but not the obligation, to invest up to Four Million Five Hundred Thousand Dollars ($4,500,000) pro rata according to the
respective amounts of Series E Preferred Stock owned by the Eligible Holders. The consummation of the December 2019 Financing contemplated by this Section 2.9(a)(ii)(2) shall occur promptly after the date, if any, as
General Atlantic elects to hold the December 2019 Financing, but in no event later than April 3, 2020; provided that the consummation of the December 2019 Financing may be tolled to the extent necessary pending

  
 7 

 
the receipt of any required regulatory or other governmental approvals. Notwithstanding the foregoing, General Atlantic shall have no right to elect to hold the December 2019 Financing if the
Company has filed a Form S-1 Registration Statement for a firmly underwritten public offering of the Company’s Common Stock; provided that if the Company does not consummate such public offering within
three (3) months of the filing of such registration statement, General Atlantic shall again have the right to elect, within fourteen (14) days after the expiration of such three- (3-) month period to
hold the December 2019 Financing in accordance with this Section 2.9(a)(ii)(2). 
 (iii) The rights of investment
in favor of General Atlantic and the Eligible Holders set forth in Sections 2.9(a)(i) and 2.9(a)(ii) above shall be for additional shares of Series E Preferred at a price of Eleven Dollars ($11.00) per share
(subject to adjustment for splits, combinations, stock dividends, recapitalizations and similar transactions) and shall be effectuated pursuant to customary documentation reasonably acceptable to General Atlantic and the Company. 

(iv) If General Atlantic or any Eligible Holder elects, in connection with either the June 2019 Financing or the December 2019 Financing
(each, a “2019 Financing”), as the case may be, to invest the full amount which General Atlantic or such Eligible Holder may be entitled to invest pursuant to Section 2.9(a)(i) or
Section 2.9(a)(ii), as applicable (each an “Electing Investor”, which term shall include General Atlantic to the extent General Atlantic invests the full amount it is entitled to invest in the applicable
2019 Financing), then such Electing Investor shall have a right of overinvestment such that if General Atlantic or any Eligible Holder fails to invest the full amount which General Atlantic or such Eligible Holder is entitled to invest in connection
with such 2019 Financing (the “Option Amount”), such Electing Investor may invest its pro rata share, based on the respective amounts of Series E Preferred Stock owned by all Electing Investors, of the Option Amount which General
Atlantic or any Eligible Holder did not invest. 
 (b) Incremental Options. If, at any time prior to July 20, 2019 (the
“Incremental Investment Period”), the Board deems it necessary to raise additional capital through one or more privately placed bona fide equity offerings for capital raising purposes, then, with respect to all such equity offerings
up to Fifty Million Dollars ($50,000,000) in the aggregate, the Company shall give written notice thereof (the “Incremental Offering Notice”) to General Atlantic and the Other Existing Holders at least twenty (20) days in
advance of the consummation thereof. Following delivery of an Incremental Offering Notice in respect of an equity offering, General Atlantic and the Other Existing Holders shall have a right, but not an obligation, to invest in such equity offering
(prior to any investment by any other Person), with such right allocated among General Atlantic and the Other Existing Holders eighty percent (80%) to General Atlantic and twenty percent (20%) to the Other Existing Holders pro rata according to the
respective amounts of Series E Preferred Stock owned by such other holders (the “Series E Option Allocation”). The foregoing right of investment in favor of General Atlantic and the Other Existing Holders shall be for a new series
of convertible preferred stock having substantially similar rights, privileges and preferences as, and pari passu with, the Series E Preferred Stock and shall be effectuated pursuant to customary documentation reasonably acceptable to General
Atlantic and the Company; provided, however, that the Board shall determine the price per share in good faith and after reasonable consultation with General 

  
 8 

 
Atlantic, and such price shall be no greater than one and three-quarters (1.75) times the Series E Original Issue Price (as defined in the Restated Certificate and subject to the adjustments
therein contained) then in effect. If the Company delivers to General Atlantic and the Other Existing Holders an Incremental Offering Notice within the Incremental Investment Period, General Atlantic and the Other Existing Holders shall exercise
their investment right (if at all) by giving written notice thereof to the Company no later than fifteen (15) days after the Incremental Offering Notice is delivered pursuant to the terms of this Agreement, and the consummation of the
additional investment contemplated by this Section 2.9(b) shall occur promptly thereafter. If General Atlantic or any Other Existing Holder does not exercise its right during such fifteen (15) day period, such right
shall terminate and be of no further force or effect with respect to General Atlantic or such Other Existing Holder, as applicable. The Incremental Investment Period and the consummation of such additional investment may be tolled to the extent
necessary pending the receipt of any required regulatory or other governmental approvals. 
 (c) The parties hereto understand and agree
that to the extent General Atlantic does not exercise its rights set forth in Section 2.9(b) with respect to an Incremental Offering Notice, the rights of the Major Holders under Section 4 of this
Agreement, to the extent applicable, shall apply to any sale of New Securities. The rights in favor of General Atlantic and the Other Existing Holders under this Section 2.9 may not be transferred, with or without the
transfer of the related equity securities of the Company beneficially owned by General Atlantic or Other Existing Holders, to any person or entity, other than an Affiliated private equity fund or pooled investment vehicle of General Atlantic or such
Other Existing Holder, as applicable. 
 2.10 Termination of Covenants. 

The covenants of the Company set forth in this Section 2, other than with respect to
Section 2.3, shall be terminated and be of no further force or effect upon the earlier of (a) immediately prior to the consummation of a Qualified Public Offering and (b) the date when no shares of Registrable
Securities or Convertible Securities shall be outstanding. 
 SECTION 3. REGISTRATION RIGHTS 

3.1 Demand Registration. 

(a) Request for Registration on Form other than Form S-3. 

Subject to the terms of this Agreement, in the event that the Company shall receive from the Initiating Holders at any time after the earlier
of (a) July 19, 2020 and (b) six (6) months after the effective date of the Company’s initial public offering of shares of Common Stock under a Registration Statement, a written request that the Company effect any Registration
with respect to all or a part of the Registrable Securities on a form other than Form S-3 for an offering the reasonably anticipated aggregate net offering proceeds of which shall be no less than Ten Million
Dollars ($10,000,000), the Company shall (i) promptly, and in any event within ten (10) days, give written notice of the proposed Registration to all other Holders and shall (ii) as soon as practicable, and in any event within sixty
(60) days, file the Registration Statement and use its reasonable best efforts to effect Registration of the Registrable Securities specified in such request, together with any Registrable Securities of any Holder joining in such request as are

  
 9 

 
specified in a written request given within thirty (30) days after written notice from the Company. The Company shall not be obligated to take any action to effect any such Registration
pursuant to this Section 3.1(a) (i) within six (6) months of the effective date of a Registration initiated by the Company or (ii) after the Company has effected three (3) such Registrations pursuant to
this Section 3.1(a) and such Registrations have been declared effective. 
 (b) Right of Deferral of
Registration on Form other than Form S-3. 
 If the Company shall furnish to all such Holders
who joined in the request a certificate signed by the President of the Company stating that, in the good faith judgment of the Board, it would be seriously detrimental to the Company for any Registration to be effected as requested under
Section 3.1(a), the Company shall have the right to defer the filing of a Registration Statement with respect to such offering for a period of not more than sixty (60) days from delivery of the request of the
Initiating Holders; provided, however, that the Company may not utilize this right more than once in any twelve (12)-month period. 
 (c)
Request for Registration on Form S-3. 
 (i) Subject to the terms of this Agreement, in the
event that the Company receives from one or more Holders of Registrable Securities, a written request that the Company effect any Registration on Form S-3 (or any successor form to Form S-3 regardless of its designation), including a Registration covering the sale or distribution of Registrable Securities from time to time by the Holders on a delayed or continuous basis pursuant to Rule 415 of the
Securities Act (a “Shelf Registration Statement”), at a time when the Company is eligible to Register securities on Form S-3 (or any successor form to Form
S-3 regardless of its designation), the Company will promptly, and in any event within ten (10) days, give written notice of the proposed Registration to all the Holders and will as soon as practicable,
and in any event within thirty (30) days, file the Registration Statement and use its best efforts to effect Registration of the Registrable Securities specified in such request, together with all or such portion of the Registrable Securities
of any Holder joining in such request as are specified in a written request delivered to the Company within twenty (20) days after written notice from the Company of the proposed Registration. There shall be no limit to the number of occasions
on which the Company shall be obligated to effect Registration under this Section 3.1(c), but the Company shall not be required to effect more than two (2) such Registrations hereunder in any twelve (12)-month period.

 (ii) In the event that a Shelf Registration Statement is effective, any Holder covered by such Shelf Registration Statement shall have
the right at any time or from time to time to elect to sell pursuant to an offering (including an underwritten offering) Registrable Securities available for sale pursuant to such registration statement (“Shelf Registrable
Securities”), so long as the Shelf Registration Statement remains in effect, and the Company shall pay all Registration Expenses in connection therewith; provided, that such offering of Shelf Registrable Securities would have an anticipated
offering price of at least One Million Dollars ($1,000,000) in the good faith discretion of the Holders. A Holder shall make such election by delivering to the Company a written notice (a “Shelf Offering Notice”) with respect to
such offering specifying the number of Shelf Registrable Securities that the holders desire to sell pursuant to such offering (the “Shelf Offering”). As promptly as practicable, but no

  
 10 

 
later than two business days after receipt of a Shelf Offering Notice, the Company shall give written notice of such Shelf Offering Notice to all other holders of Shelf Registrable Securities.
The Company, subject to Sections 3.1(e)(iv), shall include in such Shelf Offering the Shelf Registrable Securities of any other holder of Shelf Registrable Securities that shall have made a written request to the Company for inclusion in such
Shelf Offering (which request shall specify the maximum number of Shelf Registrable Securities intended to be disposed of by such holder) within seven days after the receipt of the Shelf Offering Notice. The Company shall, as expeditiously as
possible (and in any event within twenty (20) days after the receipt of a Shelf Offering Notice) use its reasonable best efforts to facilitate such Shelf Offering. Each Holder agrees that such Holder shall treat as confidential the Shelf
Offering Notice and shall not disclose or use the information contained in the Company’s notice regarding the Shelf Offering Notice without the prior written consent of the Company until such time as the information contained therein is or
becomes available to the public generally, other than as a result of disclosure by the Holder in breach of the terms of this Agreement. 

(iii) Notwithstanding the foregoing, if a Holder wishes to engage in an underwritten block trade off of a Shelf Registration Statement
(either through filing an automatic Shelf Registration Statement or through a take-down from an already existing Shelf Registration Statement), the Company and the other Holders will reasonably cooperate to effect the block trade as soon as
practicable and in accordance with market customs. 
 (d) Registration of Other Securities in Demand Registration. 

Any Registration Statement filed pursuant to the request of the Initiating Holders under Section 3.1(a) may, subject
to the provisions of Section 3.1(e), include securities of the Company other than Registrable Securities. 
 (e)
Underwriting in Demand Registration. 
 (i) Notice of Underwriting. 

If the Initiating Holders or requesting Holders under Section 3.1(c) intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so advise the Company, as a part of their request made pursuant to this Section 3.1, and the Company shall include such information in the written
notice referred to in Section 3.1(a) or 3.1(c). The right of any Holder to Registration pursuant to Section 3 shall be conditioned upon such Holder’s agreement to participate in such
underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting. 
 (ii) Inclusion of other Holders in
Demand Registration. 
 If the Company, officers or directors of the Company holding Common Stock other than Registrable Securities or
other holders of securities issued by the Company other than Registrable Securities, request inclusion in such Registration, the Initiating Holders, to the extent they deem advisable and consistent with the goals of such Registration, shall, on
behalf of all Holders, offer to any or all of the Company, such officers or directors and such holders of securities other than Registrable Securities that such securities other than Registrable Securities be included in the underwriting and may
condition such offer on the acceptance by such persons of the terms of this Section 3.1. 

  
 11 

 (iii) Selection of Underwriter in Demand Registration. 

The Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting
agreement with the representative (“Underwriter’s Representative”) of the underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable Securities being Registered by the Initiating
Holders or the requesting Holders, as the case may be, and agreed to by the Company. 
 (iv) Marketing Limitation in Demand
Registration and Shelf Offering. 
 In the event of an underwritten offering pursuant to Section 3.1(a) or
Section 3.1(c) the Underwriter’s Representative advises the Initiating Holders in writing that market factors (including, without limitation, the aggregate number of shares of Common Stock requested to be Registered,
the general condition of the market, and the status of the persons proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, then (i) first the securities other than Registrable
Securities and (ii) next the securities requested to be registered by the Company, shall be excluded from such Registration to the extent required by such limitation. If a limitation of the number of shares is still required, the Company shall
so advise all Holders that have requested to sell Registrable Securities in such offering and the number of Registrable Securities that may be included in the Registration and underwriting shall be allocated among all Holders in proportion, as
nearly as practicable, to the respective amounts of Registrable Securities owned by such Holders at the time of filing the Registration Statement. No Registrable Securities or other securities excluded from the underwriting by reason of this
Section 3.1(e)(iv) shall be included in such Registration Statement. To facilitate the allocation of shares in accordance with the above provisions, the Company or the Underwriter’s Representative may round the number
of shares allocated to any Holder to the nearest one hundred (100) shares. 
 (v) Right of Withdrawal in Demand Registration.

 If any Holder of Registrable Securities, or a holder of other securities entitled (upon request) to be included in such Registration,
disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by written notice to the Company, the underwriter and the Initiating Holders delivered at least seven (7) days prior to the effective date of the
Registration Statement. If shares are so withdrawn from the Registration and if the number of shares of Registrable Securities to be included in such registration was previously reduced as a result of marketing factors pursuant to
Section 3.1(e)(iv), the Company shall then offer to all persons who have retained the right to include securities in the Registration the right to include additional securities in the registration in an aggregate amount
equal to the number of shares so withdrawn, with such shares to be allocated among the persons requesting additional inclusion, in the manner set forth above in Section 3.1(e)(iv). Any remaining securities so withdrawn
shall also be withdrawn from the Registration Statement. 

  
 12 

 (f) Blue Sky in Demand Registration. 

In the event of any Registration pursuant to Section 3.1, the Company will exercise its reasonable best efforts to
register and qualify the securities covered by the Registration Statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably appropriate for the distribution of such securities; provided, however, that
(i) the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, and (ii) notwithstanding anything in this Agreement to the contrary, in the event any
jurisdiction in which the securities shall be qualified imposes a non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling stockholders, such expenses shall be payable pro rata by
selling stockholders. 
 3.2 Piggyback Registration. 

(a) Notice of Piggyback Registration and Inclusion of Registrable Securities. 

Subject to the terms of this Agreement, in the event the Company decides to Register any of its Common Stock (either for its own account or
the account of a security holder or holders, but excluding any registration solely in connection with an employee benefit or stock ownership plan) on a form that would be suitable for a Registration involving solely Registrable Securities, the
Company will: (i) promptly give each Holder written notice thereof (which shall include a list of the jurisdictions in which the Company intends to attempt to qualify such securities under the applicable Blue Sky or other state securities laws)
and (ii) include in such Registration (and any related qualification under Blue Sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request delivered to the Company by
any Holder within fifteen (15) days after delivery of such written notice from the Company. 
 (b) Underwriting in Piggyback
Registration. 
 (i) Notice of Underwriting in Piggyback Registration. 

If the Registration of which the Company gives notice pursuant to Section 3.2(a) is for a Registered public
offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 3.2(a). In such event the right of any Holder to Registration shall be conditioned upon
such underwriting and the inclusion of such Holder’s Registrable Securities in such underwriting to the extent provided in this Section 3. All Holders proposing to distribute their securities through such underwriting
shall (together with the Company and the other holders distributing their securities through such underwriting) enter into an underwriting agreement with the Underwriter’s Representative for such offering. The Holders shall have no right to
participate in the selection of the underwriters for an offering pursuant to this Section 3.2. 

  
 13 

 (ii) Marketing Limitation in Piggyback Registration. 

In the event the Underwriter’s Representative advises the Holders seeking Registration of Registrable Securities pursuant to
Section 3.2 in writing that market factors (including, without limitation, the aggregate number of shares of Common Stock requested to be Registered, the general condition of the market, and the status of the persons
proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, the Underwriter’s Representative (subject to the allocation priority set forth in
Section 3.2(b)(iii)) may: 
  

	 	(A)	 in the case of the Company’s initial Registered public offering, exclude some or all Registrable
Securities from such Registration and underwriting; and 

  

	 	(B)	 in the case of any subsequent registered public offering, limit the number of shares of Registrable Securities
to be included in such Registration and underwriting to not less than twenty five percent (25%) of the total number of securities included in such offering. 

(iii) Allocation of Shares in Piggyback Registration. 

In the event that the Underwriter’s Representative limits the number of shares to be included in a Registration pursuant to
Section 3.2(b)(ii), the number of shares to be included in such Registration shall be allocated (subject to Section 3.2(b)(ii)) in the following manner: The number of shares, if any, that may be
included in the Registration and underwriting by selling stockholders shall first be allocated among all the requesting Holders pro rata according to the respective amounts of Registrable Securities owned by such requesting Holders and then among
all other holders of securities other than Registrable Securities requesting and legally entitled to include shares in such Registration, in proportion, as nearly as practicable, to the respective amounts of securities (including Registrable
Securities) that such Holders and such other holders would otherwise be entitled to include in such Registration. No Registrable Securities or other securities excluded from the underwriting by reason of this
Section 3.2(b)(iii) shall be included in the Registration Statement. To facilitate the allocation of shares in accordance with the above provisions, the Company or the Underwriter’s Representative may round the number
of shares allocated to any Holder to the nearest one hundred (100) shares. 
 (iv) Withdrawal in Piggyback Registration.

 If any Holder disapproves of the terms of any such underwriting, he may elect to withdraw therefrom by written notice to the Company and
the underwriter delivered at least the later of seven (7) days prior to the effective date of the Registration Statement and seven (7) days after receipt by such Holder of the terms of such underwriting. Any Registrable Securities or other
securities excluded or withdrawn from such underwriting shall be withdrawn from such Registration. 

  
 14 

 (c) Blue Sky in Piggyback Registration. 

In the event of any Registration of Registrable Securities pursuant to Section 3.2, the Company will exercise its
best efforts to Register and qualify the securities covered by the Registration Statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably appropriate for the distribution of such securities; provided,
however, that (i) the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, and (ii) notwithstanding anything in this Agreement to the contrary, in
the event any jurisdiction in which the securities shall be qualified imposes a non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling stockholders, such expenses shall be payable
pro rata by selling stockholders. 
 3.3 Expenses of Registration. 

All Registration Expenses incurred in connection with three (3) Registrations pursuant to Section 3.1(a), all
Registrations pursuant to Section 3.1(c) (Form S-3) and all Registrations pursuant to Section 3.2 shall be borne by the Company, regardless of whether the
Holders have sold any securities in such offering. All Registration Expenses incurred in connection with any other registration, qualification or compliance shall be apportioned among the Holders and other holders of the securities so registered on
the basis of the number of shares so registered. Notwithstanding the above, the Company shall not be required to pay for any expenses of any Registration proceeding begun pursuant to Section 3.1 if the Registration request
is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be Registered (which Holders shall bear such expenses), unless the Holders of a majority of the Registrable Securities agree to forfeit their
right to demand one of their Registrations pursuant to Section 3.1; provided further, however, that if at the time of such withdrawal, the Holders have learned of a Material Adverse Event not known to
the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such Material Adverse Event, then the Holders shall not be required to pay any of such expenses and
shall retain their rights pursuant to Section 3.1. All Selling Expenses shall be borne by the respective holders of the securities Registered pro rata on the basis of the number of shares registered on their behalf. 

3.4 Registration Procedures. 

The Company will keep each Holder whose Registrable Securities are included in any Registration pursuant to this Agreement advised as to the
initiation and completion of such Registration. At its expense the Company will: (a) use its best efforts to keep such Registration effective for a period of one hundred and twenty days (120) (or in the case of a Shelf Registration Statement,
three (3) years) or until the Holder or Holders have completed the distribution described in the Registration Statement relating thereto, whichever first occurs; (b) prepare and file with the Commission such amendments and supplements to
such Registration Statement, and the prospectus used in connection with such Registration Statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such Registration Statement;
(c) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; (d) use its commercially reasonable
efforts to cause all such Registrable Securities covered by such Registration Statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by
the Company are then listed; (e) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and 

  
 15 

 
provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such Registration; (f) promptly make available for inspection by the selling
Holders, any managing underwriter(s) participating in any disposition pursuant to such Registration Statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other
records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney,
accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such Registration Statement and to conduct appropriate due diligence in connection therewith; and (g) furnish such number of prospectuses
(including preliminary prospectuses) and other documents as a Holder from time to time may reasonably request. 
 The Company will notify
each seller of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus
included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in
light of the circumstances then existing, and following such notification promptly prepare and furnish to such seller a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter
delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or
incomplete in light of the circumstances then existing. 
 3.5 Information Furnished by Holder. 

It shall be a condition precedent of the Company’s obligations under this Agreement that each Holder of Registrable Securities included
in any Registration furnish to the Company such information regarding such Holder and the distribution proposed by such Holder or Holders as the Company may reasonably request. 

3.6 Indemnification. 

(a) Company’s Indemnification of Holders. 

To the extent permitted by law, the Company will indemnify each Holder, each of its officers, directors and constituent partners, legal
counsel for the Holders, and each person controlling such Holder, with respect to which Registration, qualification or compliance of Registrable Securities has been effected pursuant to this Agreement, and each underwriter, if any, and each person
who controls any underwriter, against all claims, losses, damages or liabilities (or actions in respect thereof) to the extent such claims, losses, damages or liabilities arise out of or are based upon any untrue statement (or alleged untrue
statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such Registration, qualification or compliance, or are based on any omission (or alleged omission) to state
therein a material fact required to be stated therein or 

  
 16 

 
necessary to make the statements therein not misleading, or any violation by the Company of any rule or regulation promulgated under the Securities Act applicable to the Company and relating to
action or inaction required of the Company in connection with any such Registration, qualification or compliance; and the Company will reimburse each such Holder, each such underwriter and each person who controls any such Holder or underwriter, for
any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action; provided, however, that the indemnity contained in this Section 3.6(a)
shall not apply to amounts paid in settlement of any such claim, loss, damage, liability or action if settlement is effected without the consent of the Company (which consent shall not unreasonably be withheld); and provided, further, that the
Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based upon any untrue statement or omission based upon written information furnished to the Company by such Holder,
underwriter, or controlling person and expressly stated to be for use in connection with the offering of securities of the Company. 
 (b)
Holder’s Indemnification of Company. 
 To the extent permitted by law, each Holder will, if Registrable
Securities held by such Holder are included in the securities as to which such Registration, qualification or compliance is being effected pursuant to this Agreement, indemnify the Company, each of its directors and officers, each legal counsel and
independent accountant of the Company, each underwriter, if any, of the Company’s securities covered by such a Registration Statement, each person who controls the Company or such underwriter within the meaning of the Securities Act, and each
other such Holder, each of its officers, directors and constituent partners and each person controlling such other Holder, against all claims, losses, damages or liabilities (or actions in respect thereof) to the extent that such claims, losses,
damages or liabilities (or actions in respect thereof) arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in
connection with such Registration; and will reimburse the Company, such Holders, such directors, officers, partners, persons, law and accounting firms, underwriters or control persons for any legal and any other expenses reasonably incurred in
connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in
such Registration Statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by such Holder expressly for use in connection with the offering of securities of the
Company, provided, however, that each Holder’s liability under this Section 3.6(b) shall be several, and not joint with other Holders, and shall not exceed such Holder’s proceeds from the offering of securities
made in connection with such Registration. 
 (c) Indemnification Procedure. 

Promptly after receipt by an indemnified party under this Section 3.6 of notice of the commencement of any action,
such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 3.6, notify the indemnifying party in writing of the commencement thereof and generally summarize
such action. The indemnifying party shall have the right to participate in and to assume the defense of such claim; provided, 

  
 17 

 
however, that the indemnifying party shall be entitled to select counsel for the defense of such claim with the approval of any parties entitled to indemnification, which approval shall not be
unreasonably withheld; provided further, however, that if either party reasonably determines that there may be a conflict between the position of the indemnifying party and the indemnified party in conducting the defense of such action, suit or
proceeding by reason of recognized claims for indemnity under this Section 3.6, then counsel for such party shall be entitled to conduct the defense to the extent reasonably determined by such counsel to be necessary to
protect the interest of such party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such action, shall relieve such indemnifying party, to
the extent so prejudiced, of any liability to the indemnified party under this Section 3.6, but the omission so to notify the indemnifying party will not relieve such party of any liability that such party may have to any
indemnified party otherwise other than under this Section 3.6. 
 (d) Contribution. 

To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 3.6 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction
and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 3.6 provides for indemnification in such
case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 3.6, then, and in each such case, such parties will
contribute to the aggregate claims, losses, damages or liabilities (or actions in respect thereof) to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the
indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such claim, loss, damage or liability, as well as to reflect any other relevant equitable considerations. The relative fault
of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any
such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a
Holder’s liability pursuant to this Section 3.6(d), when combined with the amounts paid or payable by such Holder pursuant to Section 3.6(b), exceed such Holder’s proceeds from the
offering of securities made in connection with such Registration, except in the case of willful misconduct or fraud by such Holder. 

  
 18 

 3.7 Limitations on Registration Rights Granted to Other Securities. 

From and after the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any
securities of the Company providing for the granting to such holder of any information or Registration rights, except that, with the consent of the Holders of a majority of the Registrable Securities then outstanding, additional holders may be added
as parties to this Agreement with regard to any or all securities of the Company held by them. Any such additional parties shall execute a counterpart of this Agreement, and upon execution by such additional parties and by the Company, shall be
considered an Investor for all purposes of this Agreement. The additional parties and the additional Registrable Securities shall be identified in an amendment to Schedule A hereto. 

3.8 Transfer of Rights. 

The rights to information under Section 2 and the right to cause the Company to Register securities granted by the
Company to the Investors under Sections 3.1 and 3.2 may be assigned by any Holder to a transferee or assignee of any Convertible Securities or Registrable Securities acquiring at least five percent (5%) of the outstanding Registrable
Securities on an as-converted to Common Stock basis, or all (whichever is lesser) of such Holder’s Registrable Securities (equitably adjusted for all stock splits, subdivisions, stock dividends,
combinations and the like); provided, however, that (i) the Company must receive prompt written notice prior to the time of said transfer, stating the name and address of said transferee or assignee and identifying the securities with respect
to which such rights are being assigned, (ii) the transferee or assignee of such rights must not be a person deemed by the Board, in its best judgment, to be a competitor or potential competitor of the Company and (iii) the transferee
agrees to be bound by the terms and conditions of this Agreement. Notwithstanding the limitation set forth in the foregoing sentence respecting the minimum number of Registrable Securities which must be transferred, (a) any Holder which is a
partnership, limited liability company or corporation may transfer such Holder’s rights (1) to entities affiliated directly or indirectly with such partnership, the manager of such limited liability company, such limited liability company
or such corporation, (2) any partner (or retired or incoming partner), member (or retired member) or stockholder of such partnership, limited liability company or corporation, respectively, (3) the spouse, siblings, lineal descendants or
ancestors of any such partner (or retired partner), member (or retired member) or stockholder, (4) the estate of any such partner (or retired partner), member (or retired member) or stockholder and (5) any custodian or trustee for the
benefit of any such partner (or retired partner), member (or retired member) or stockholder, as the case may be, (b) any Holder which is a natural person may transfer such Holder’s rights to any immediate family member or to any trust
created for the benefit of such Holder or his or her immediate family members, and (c) any Holder that holds shares in its capacity as trustee, manager or custodian of a trust may transfer such Holder’s Registration rights to a replacement
trustee, manager or custodian of the relevant trust, subject in each case to such transferee’s agreeing to be bound by the rights and restrictions of this Agreement and without restriction as to the number or percentage of shares acquired by
any such transferee. The rights under Sections 2, 3.1 and 3.2 may be assigned by an Investor only as provided in this Section 3.8. 

  
 19 

 3.9 Market Stand-off. 

If requested in writing by the underwriters for the initial Qualified Public Offering, each holder of Registrable Securities who is a party to
this Agreement shall agree not to sell publicly any shares of Registrable Securities or any other securities of the Company (other than shares of Registrable Securities or other securities of the Company being registered in such offering), without
the consent of such underwriters, for a period of not more than one hundred eighty (180 days) following the effective date of the registration statement relating to the initial Qualified Public Offering; provided, however, that the
Company shall use commercially reasonable efforts to convince such managing underwriters to allow for alternative means of liquidity for the holders if, in the opinion of such managing underwriters, such liquidity can be provided without an adverse
impact on such initial Qualified Public Offering; and, provided, further, however, that all persons entitled to Registration rights with respect to shares of Common Stock who are not parties to this Agreement, all other persons
selling shares of Common Stock in such offering, all executive officers and directors of the Company and all stockholders holding greater than one percent (1%) of the Company shall also have agreed not to sell publicly their Common Stock under the
circumstances and pursuant to the terms set forth in this Section. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such
agreements, based on the number of shares subject to such agreements. 
 3.10 No-Action Letter or
Opinion of Counsel in Lieu of Registration; Conversion of Preferred Stock. 
 Notwithstanding anything else in this Agreement, if the
Company shall have obtained from the Commission a “no-action” letter in which the Commission has indicated that it will take no action if, without Registration under the Securities Act, any Holder
disposes of Registrable Securities covered by any request for Registration made under this Agreement in the specific manner in which such Holder proposes to dispose of the Registrable Securities included in such request (such as including, without
limitation, the inclusion of such Registrable Securities in an underwriting initiated by either the Company or the Holders), or if in the opinion of counsel for the Company concurred in by counsel for such Holder, which concurrence shall not be
unreasonably withheld, no Registration under the Securities Act is required in connection with such disposition, the shares included in such request shall not be eligible for Registration under this Agreement; provided, however, that any Registrable
Securities not so disposed of shall be eligible for Registration in accordance with the terms of this Agreement with respect to other proposed dispositions to which this Section 3.10 does not apply. The Registration rights
of the Holders of Convertible Securities set forth in this Agreement are conditioned upon the conversion of the Convertible Securities with respect to which Registration is sought into Common Stock prior to the effective date of the Registration
Statement. 
 3.11 Sale of Preferred Stock to Underwriter. 

Notwithstanding any provision in this Agreement to the contrary, in lieu of converting any Convertible Securities prior to the filing of any
Registration Statement filed pursuant to this Agreement, the holder of such Convertible Securities may sell such Convertible Securities to the underwriters of the offering being Registered upon the undertaking of such

  
 20 

 
underwriters to convert the Convertible Securities on or prior to the closing date of the offering. The Company agrees to cause the Common Stock issuable on the conversion of the Convertible
Securities to be issued within such time period as will permit the underwriters to make and complete the distribution contemplated by the underwriting. 

3.12 Rule 144 Requirements. 

With a view to making available to the Holders the benefits of Rule 144 under the Securities Act and any other rule or regulation of the
Commission that may at any time permit a Holder to sell securities of the Company to the public without Registration or pursuant to a Registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in Rule 144, at all times after the
effective date of the Registration Statement filed by the Company for the initial public offering; 
 (b) use commercially reasonable
efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the initial public offering),
the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such
other information as may be reasonably requested in availing any Holder of any rule or regulation of the Commission that permits the selling of any such securities without Registration (at any time after the Company has become subject to the
reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

3.13 Termination of Company Agreements. 

The Registration rights set forth in Sections 3.1 and 3.2 shall terminate five (5) years after consummation of a Qualified
Public Offering or, as to any Holder, at any time following the consummation of a Qualified Public Offering, when such Holder is entitled to sell all of such Investor’s Registrable Securities pursuant to Rule 144 of the Securities Act without
any limitations as to volume or manner of sale. 

  
 21 

 SECTION 4. RIGHT OF FIRST REFUSAL 

4.1 Right of First Refusal. 

(a) Subject to subsection (b) of this Section 4.1 and Section 4.2 through
Section 4.8 hereof, the Company hereby grants to each Major Holder the right of first refusal to purchase such Investor’s pro rata share of New Securities (as defined in Section 4.2) that the
Company may from time to time propose to sell and issue (the “Right of First Refusal”). For purposes of the Right of First Refusal, an Investor’s pro rata share (the “Pro Rata Share”) shall be equal to that
number or amount of New Securities to be sold minus all New Securities (if any) agreed to be purchased by General Atlantic pursuant to Section 4.1(b) below, multiplied by a fraction, the numerator of which shall be the
number of shares of Common Stock issuable upon the conversion of all Convertible Securities owned by such Investor (and without taking into account any unexercised options or warrants) and the denominator of which shall be the total number of shares
of the Company’s Common Stock issuable upon the conversion of all Convertible Securities held by the Investors (including, for the avoidance of doubt, shares held by General Atlantic, in the event that General Atlantic also exercises its rights
under Section 4.1(b) below with respect to such offering) deemed to be outstanding (and without taking into account any unexercised options or warrants). Notwithstanding the foregoing, any Investor may, at the time it
accepts the Company’s offer, subscribe to purchase any or all of the New Securities offered (“Oversubscription Securities”) that may be available as a result of the rejection, or partial rejection, of the offer by other
Investors; provided, however, that, so long as General Atlantic’s rights under Section 4.1(b) below have not terminated, any allocation of Oversubscription Securities shall first be allocated to General
Atlantic as set forth in Section 4.1(b) below with any remaining Oversubscription Securities being allocated among those other Investors who so subscribe to purchase Oversubscription Securities. All such remaining
Oversubscription Securities shall be allocated among those Investors subscribing to purchase them in proportion to the number of shares of Common Stock issuable upon conversion of all Convertible Securities held by each such Investor relative to the
number of shares of Common Stock issuable upon conversion of all Convertible Securities held by all Investors subscribing to purchase the remaining Oversubscription Securities. 

(b) Notwithstanding subsection (a) of this Section 4.1, prior to the Company’s initial public offering,
General Atlantic shall have the right (but not the obligation) to purchase up to fifty percent (50%) of any New Securities until such time as General Atlantic has invested One Hundred Million Dollars ($100,000,000) in aggregate capital in the
Company (including its purchase of shares of Series E Preferred Stock and any securities acquired pursuant to Section 2.9 of this Agreement), following which it will have the right to acquire its Pro Rata Share of any
offering of New Securities pursuant to subsection (a) of this Section 4.1. Any allocations of New Securities made pursuant to subsection (a) of this Section 4.1 shall be made after
taking into account funds elected to be invested by General Atlantic pursuant to this subsection (b). If (i) with respect to the first offering of New Securities with a value in excess of Twenty Million Dollars ($20,000,000) which is
subsequently consummated on the offered terms within ninety (90) days in accordance with Section 4.5, General Atlantic does not elect to acquire fifty percent (50%) of the New Securities in such offering or
(ii) General Atlantic fails to purchase at least Ten Million Dollars ($10,000,000) of Series E Preferred Stock pursuant to the Purchase Agreement, the rights of General Atlantic specified in this subsection (b) shall terminate and be of no
further force or effect. For the avoidance of doubt, General Atlantic’s failure to exercise its rights in Section 2.9(b) above shall not affect its rights in this subsection (b). 

  
 22 

 4.2 Definition of New Securities. 

“New Securities” shall mean any shares of Common Stock or Preferred Stock of the Company, whether now authorized or not, and
rights, options, or warrants to purchase such shares of Common Stock or Preferred Stock, and all other securities having equity features, such as convertible notes or notes issued in conjunction with options or warrants; provided that “New
Securities” shall not include: 
 (a) securities issuable upon conversion of the Preferred Stock, or as a dividend or distribution on
the Preferred Stock; 
 (b) shares of Common Stock issued or deemed issued (or options to purchase shares of Common Stock granted) to
officers, directors, consultants or employees of the Company, pursuant to a stock option plan approved by the Board; 
 (c) securities
issued in connection with research and development partnerships, licensing, corporate partnering, distribution arrangements, collaborative arrangements or similar transactions approved by the Board; provided that none of the foregoing issuances are
primarily for equity financing purposes; 
 (d) securities to financial institutions or lessors issued in connection with commercial credit
arrangements, equipment financings, commercial property lease transactions, or similar transactions approved by the Board; provided that none of the foregoing issuances are primarily for equity financing purposes; 

(e) securities issuable to General Atlantic pursuant to Section 2.9 above; and 

(f) shares of Common Stock issued or issuable for consideration other than cash pursuant to a merger, consolidation, acquisition or similar
business combination, provided that such issuance has been approved by the holders of at least sixty percent (60%) of the combined voting power of the Preferred Stock, voting together as a separate class on an as converted to Common Stock basis.

 4.3 Waiver of Right of First Refusal. In the event that the Right of First Refusal in Section 4.1(a) is
waived pursuant to Section 5.8 hereof with respect to an issuance of New Securities by the Company, and any Investor that consented to such waiver pursuant to Section 5.8 (a “Waiving
Investor”) is nevertheless permitted to purchase any such New Securities, each Investor that is not a Waiving Investor shall be entitled to purchase its Adjusted Pro Rata Share (as defined below) of such New Securities upon the terms and
conditions set forth in Section 4.1(a). For purposes of this Section 4.3, an Investor’s “Adjusted Pro Rata Share” of the New Securities subject to the waiver described herein
shall be equal to (i) such Investor’s Pro Rata Share of such New Securities multiplied by (ii) the highest percentage of any Waiving Investor’s Pro Rata Share that such Waiving Investor is permitted to purchase. For example, if
only one Waiving Investor is permitted to purchase any New Securities and it is permitted to purchase 50% of its Pro Rata Share of the New Securities, each Investor’s Adjusted Pro Rata 

  
 23 

 
Share shall be 50% of its Pro Rata Share. For another example, if one Waiving Investor is permitted to purchase 60% of its Pro Rata Share and another Waiving Investor is permitted to purchase
110% of its Pro Rata Share, each Investor’s Adjusted Pro Rata Share shall be 110% of its Pro Rata Share. This Section 4.3 shall in no way limit General Atlantic’s rights to purchase New Securities pursuant to
Section 4.1(b) or Oversubscription Securities pursuant to Section 4.1(a). 
 4.4
Notices. 
 In the event the Company proposes to undertake an issuance of New Securities, it shall give each Investor written notice
(the “Notice”) of its intention, describing the type of New Securities, the price, and the principal terms upon which the Company proposes to issue the same. Each Investor shall have twenty (20) days from the delivery of the
Notice to agree to purchase up to the Investor’s Pro Rata Share (and, in the case of General Atlantic, its allocable share pursuant to Section 4.1(b)) plus any Oversubscription Securities for the price and upon the
terms specified in the Notice by giving written notice to the Company and stating therein the quantity of New Securities and Oversubscription Securities to be purchased. The consummation of any purchase of New Securities by the Investors may be
tolled to the extent necessary pending the receipt of any required regulatory or other governmental approvals. 
 4.5 Failure to Exercise
Right. 
 In the event an Investor does not elect to purchase all of such Investor’s Pro Rata Share (and, in the case of General
Atlantic, its allocable share pursuant to Section 4.1(b)) of the New Securities pursuant to Section 4.1 and such New Securities are not purchased by other Investors, the Company shall have ninety
(90) days after the last date on which any Investor’s right to purchase lapsed to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within ninety (90) days from
the date of said agreement) to sell the New Securities respecting which such Investor’s option was not exercised, at or above the price and upon terms not materially more favorable to the purchasers of such securities than the terms specified
in the initial Notice given in connection with such sale. In the event the Company has not sold the New Securities within said 90-day period (or sold and issued New Securities in accordance with the foregoing
within ninety (90) days from the date of said agreement), the Company shall not thereafter issue or sell any New Securities without first offering such New Securities to the Investors in the manner provided in this
Section 4. 
 4.6 Rights of Affiliated Investors. 

For the purposes of this Section 4, Investors who are Affiliates of one or more other Investors shall, at the
election of an Investor and one or more such Affiliates, be treated as a group (an “Investor Group”). Members of an Investor Group shall have the right to reallocate the rights granted by this Section 4
among themselves as they determine. 
 4.7 Assignment. 

The Right of First Refusal set forth in this Section 4 may not be assigned or transferred, except that each Investor
shall have the right to assign its right to purchase securities under this Section 4 to any Affiliate of such Investor; provided such Affiliate agrees in writing with the Company and the Investors, prior to and as a
condition precedent to such transfer, to be bound by all the provisions of Sections 3, 4, 5 and 6 of this Agreement and the Voting Agreement. 

  
 24 

 4.8 Termination. 

Except as provided in Section 4.1(b) above, the rights of first refusal granted under this
Section 4 shall terminate on and be of no further force or effect upon the earlier of (i) the effective date of the Company’s registration statement filed in connection with a Qualified Public Offering, and
(ii) a Liquidating Transaction (as defined in the Certificate of Incorporation). 
 SECTION 5. MISCELLANEOUS. 

5.1 Entire Agreement; Successors and Assigns. 

This Agreement, the Purchase Agreement, the Transaction Agreements (as defined in the Purchase Agreement), the Restated Certificate and the
exhibits hereto constitute the entire contract between the Company and the Investors relative to the subject matter hereof. Subject to the exceptions specifically set forth in this Agreement, the terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective executors, administrators, heirs, successors and assigns of the parties. Upon the execution and delivery of this Agreement by the requisite Investors and the Company, the Prior Agreement shall
thereafter be of no further force and effect and is hereby amended and restated herein. 
 5.2 Aggregation of Stock. 

All Convertible Securities and Registrable Securities held or acquired by affiliated entities or persons shall be aggregate together for the
purpose of determining the availability of any rights under this Agreement. 
 5.3 Severability and Governing Law. 

Should any Section or any part of a Section within this Agreement be rendered void, invalid or unenforceable by any court of law for any
reason, such invalidity or unenforceability shall not void or render invalid or unenforceable any other Section or part of a Section in this Agreement. THE LAWS OF THE STATE OF DELAWARE SHALL GOVERN THE VALIDITY AND INTERPRETATION OF THIS AGREEMENT
AND THE PERFORMANCE BY THE PARTIES HERETO OF THEIR RESPECTIVE DUTIES AND OBLIGATIONS HEREUNDER. 
 5.4 Counterparts. 

This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 

  
 25 

 5.5 Headings. 

The headings of the Sections of this Agreement are for convenience and shall not by themselves determine the interpretation of this Agreement.

 5.6 Notices. 
 Any
notice required or permitted hereunder shall be given in writing and shall be conclusively deemed effectively given upon personal delivery, or five (5) days after deposit in the United States mail, by registered or certified mail (or airmail,
if notice shall be sent outside the United States), postage prepaid, or two (2) days after delivery to a nationally known air courier company, addressed (i) if to the Company, to the Company’s address as set forth below the
Company’s name on the signature page of this Agreement, and (ii) if to an Investor, to such Investor’s address as set forth on Schedule A. Any notice sent outside the United States shall also be telexed or telecopied. 

5.7 Attorneys’ Fees. 

If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to
reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

5.8 Amendment of Agreement; Waivers. 

Any provision of this Agreement may be amended or waived by a written instrument signed by (i) the Company, (ii) Persons holding at
least sixty percent (60%) of the Registrable Securities and (iii) Persons holding at least sixty percent (60%) of the combined voting power of the Series A-1 Preferred Stock, Series B Preferred Stock,
Series C Preferred Stock, Series C-1 Preferred Stock, Series D Preferred Stock and Series E Preferred Stock, voting together as a separate class on an as converted to Common Stock basis; provided, that any
amendment or waiver of this Agreement in a manner that adversely affects the rights of the holders of any series of Preferred Stock in manner that is different from other similarly situated holders of any series of Preferred Stock shall also require
the written consent of the holders of a majority of the voting power of such adversely affected series of Preferred Stock; provided, further, that any amendment or waiver of this Agreement in a manner that adversely affects any Investor in a manner
different from any other Investor shall also require the written consent of the adversely affected Investor; provided, further, that any amendment or waiver of General Atlantic’s rights in Section 2.9 or
Section 4.1 or of this proviso, shall also require the written consent of General Atlantic. Any amendment or waiver effected in accordance with this Section 5.8 shall be binding upon the Company
and all Holders and each of their respective successors and assigns. 
 [Signature pages follow] 

  
 26 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the day and year first above written. 
  

							
	COMPANY:	 	SONENDO, INC.
				
		 		 	By:	 	/s/ Bjarne Bergheim
		 		 		 	Bjarne Bergheim,
		 		 		 	President and Chief Executive Officer
				
		 		 		 	Address:
				
		 		 		 	 26051 Merit Circle, Suite 102
 Laguna Hills,
CA 92653

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

	
	INVESTOR:
	
	/s/ Bjarne Bergheim
	 Bjarne Bergheim
  

Address:
  

26362 Ibeza Road

Mission Viejo, CA 92692 

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

	
	INVESTOR:
	
	/s/ Olav B. Bergheim
	 Olav B. Bergheim

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

	
	INVESTOR:
	
	/s/ Troy M. Bremer
	 Troy M. Bremer
  

Address:
  

47 Sparrowhawk

Irvine, CA 92604

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

	
	INVESTOR:
	
	 CPV Holding, LLC

	
	/s/ Andrew B. Cohen
	 Name: Andrew B. Cohen

Title: Authorized Signatory
  

Address:
  

72 Cummings Point Road

Stamford, CT 06902

Email: Andrew.Cohen@CohenPV.com
  

with a copy to:
  

Point72, L.P.

72 Cummings Point Road

Stamford, CT 06902

Attn: Peter Goodwin

Email: Peter.Goodwin@Point72.com 

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

	
	INVESTOR:
	
	CVF, LLC
	
	 /s/ Richard H. Robb

	Richard H. Robb

  

	
	Address:
	
	222 N. La Salle Street
	Suite 200
	Chicago, IL 60601

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

	
	INVESTOR:
	
	FJORDINVEST (CAYMAN) II LTD.
	
	/s/ Olav B. Bergheim
	Name: Olav B. Bergheim
	Its: Chief Executive Officer

  

	
	Address:
	
	26051 Merit Circle
	Suite 102
	Laguna Hills, CA 92653

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

	
	INVESTOR:
	
	FJORD CAPITAL PARTNERS I, L.P.
	
	By: Fjord Venture Partners I, LLC
	 Its: General Partner

	
	/s/ Olav B. Bergheim
	Olav B. Bergheim
	Manager

  

	
	Address:
	
	26051 Merit Circle, Suite 102
	Laguna Hills, CA 92653
	Attn: Olav Bergheim

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

	
	INVESTOR:
	
	FJORD VENTURES LLC
	
	/s/ Olav B. Bergheim
	Olav B. Bergheim
	President

  

	
	Address:
	
	26051 Merit Circle, Suite 102
	Laguna Hills, CA 92653

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

	
	INVESTOR:
	
	FJORDINVEST, LLC
	a Nevada limited liability company
	
	/s/ Olav B. Bergheim
	Olav B. Bergheim
	Manager

  

	
	Address:
	
	c/o Becker Financial
	2082 Michelson Drive, Suite 302
	Irvine, CA 92612

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	FJORDINVEST (CAYMAN) LTD.
		
	By:	 	/s/ Olav B. Bergheim
	 Name: Olav B. Bergheim

	Title: Chief Executive Officer
	
	Address:
	
	 26051 Merit Circle, Suite 102

Laguna Hills, CA 92653 

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	 GENERAL ATLANTIC (SOI), L.P.

	
	By: General Atlantic (SPV) GP, LLC, its general partner
	
	 By: General Atlantic, LLC its sole member

		
	By:	 	/s/ Thomas J. Murphy
	 Name: Thomas J. Murphy

	Title: Managing Director
	
	Address:
	
	 c/o General Atlantic Service Company, LLC

55 East 52nd Street, 32nd Floor

New York, NY 10055

Attention: Gordon Cruess

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	JMR CAPITAL LIMITED
		
	By:	 	/s/ Grace Rusli

 
			
	Name:	 	Grace Rusli
	Title:	 	Vice President
	
	Address:
	
	c/o Kitano Capital
	2711 N. Haskell Avenue
	Suite 1650
	Dallas, TX 75204

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the day and year first above written. 
  

			
	INVESTOR:
	
	MERITECH CAPITAL AFFILIATES IV, L.P.
		
	By:	 	Meritech Capital Associates IV L.L.C., its General Partner
		
	By:	 	/s/ Paul Madera
		 	Paul Madera, a managing member
	
	MERITECH CAPITAL PARTNERS IV, L.P.
		
	By:	 	 Meritech Capital Associates IV L.L.C., its General Partner

		
	By:	 	/s/ Paul Madera
		 	Paul Madera, a managing member
	
	Address:
	
	245 Lytton Avenue, Suite 125 
Palo Alto, CA 94301 
Attn: Joel Backman 
Fax: (650) 475-2222

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the day and year first above written. 
  

	
	INVESTOR:
	
	/s/ Hugh Andrew Neuharth
	Hugh Andrew Neuharth
	
	Address:
	
	 19 White Sail 
Laguna Niguel, CA 92677

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the day and year first above written. 
  

			
	INVESTOR:
	
	ORBIMED PRIVATE INVESTMENTS IV, LP
		
	By:	 	OrbiMed Capital GP IV LLC, its General Partner
		
	By:	 	OrbiMed Advisors LLC, its Managing Member
		
	By:	 	/s/ Carl Gordon
		 	Name: Carl Gordon
		 	Title: Member
	
	Address:
	
	 OrbiMed Private Investments IV, LP

OrbiMed Advisors, LLC
 601 Lexington Avenue, 54th Floor

New York, NY 10022

  
 [Signature Page to Third
Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	PENSCO Trust Company,
	Custodian
	FBO Olav Bergheim IRA.
		
	By:	 	/s/ Sara Estes

 
			
	Name:	 	Sara Estes
	Title:	 	Authorized Signatory

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND
		
	By:	 	/s/ James H. Mannix

 
			
	Name:	 	James H. Mannix
	Title:	 	C.O.O.
	
	Address:
	
	51 Astor Place, 10th Floor
	New York, New York 10003
	Attn: Sandeep Dixit

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	SECURITY PACIFIC FINANCE, LTD.
		
	By:	 	/s/ Ross Cameron
		
	By:	 	/s/ Sam Ozanne
	
	Address:
	
	c/o RBC Trustees (Guernsey) Ltd.
	P.O. Box 48 Canada Court
	GYI 38Q St. Peter Port
	Guernsey, Channel Islands

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	Meridian Small Cap Growth Fund
	By: its Investment Adviser
	ArrowMark Colorado Holdings, LLC
		
	By:	 	/s/ David Corkins

 
			
	Name:	 	David Corkins
	Title:	 	Managing Member

  

			
	ArrowMark Life Science Fund, LP
	By: its General Partner
	AMP Life Science GP, LLC
		
	By:	 	/s/ David Corkins

 
			
	Name:	 	David Corkins
	Title:	 	Managing Member

  

			
	ArrowMark Fundamental Opportunity
	Fund, L.P.
	By: its General Partner
	ArrowMark Partners GP, LLC
		
	By:	 	/s/ David Corkins

 
			
	Name:	 	David Corkins
	Title:	 	Managing Member

  

			
	Lookfar Investments, LLC
		
	By:	 	/s/ David Corkins

 
			
	Name:	 	David Corkins
	Title:	 	Managing Member
	
	Address:
	100 Fillmore Street, Suite 325
	Denver, CO 80206

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	Broadfin Healthcare Master Fund Ltd.
		
	By:	 	/s/ Kevin Kotler

 
			
	Name:	 	Kevin Kotler
	Title:	 	Director
	
	Address:
	300 Park Avenue
	25th Floor
	New York, New York 10022

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	EW Healthcare Partners Fund 2, L.P.
		
	By:	 	EW Healthcare Partners Fund 2-GP, L.P., its General Partner
	By:	 	EW Healthcare Partners Fund 2-UGP, LLC, its General Partner
		
	By:	 	/s/ Martin P. Sutter
	Name:	 	Martin P. Sutter
	Title:	 	Managing Director

  

			
	EW Healthcare Partners Fund 2-A, L.P.
		
	By:	 	EW Healthcare Partners Fund 2-GP, L.P., its General Partner
	By:	 	EW Healthcare Partners Fund 2-UGP, LLC, its General Partner
		
	By:	 	/s/ Martin P. Sutter
	Name:	 	Martin P. Sutter
	Title:	 	Managing Director
	
	Address:
	21 Waterway Avenue, Suite 225
	The Woodlands, TX 77380

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amended and Restated
Investors’ Rights Agreement as of the day and year first above written. 
  

			
	INVESTOR:
	
	Redmile Private Investments II, L.P.
		
	By:	 	/s/ Joshua Garcia
	Name:	 	Joshua Garcia
	Title:   Chief Financial Officer and Authorized Signatory of Redmile Group, LLC, the managing member of Redmile Private Investments II (GP), LLC, its general partner
	
	Address:
	
	Redmile Private Investments II, L.P.
	c/o Redmile Group, LLC
	One Letterman Drive
	Suite D3-300
	San Francisco, CA 94129

 [Signature Page to Third Amended and Restated Investors’ Rights Agreement of Sonendo, Inc.] 

 SCHEDULE A 

INVESTORS 
 Bjarne Bergheim 

Troy Bremer 
 Thomas R. Engels

 Daniel and Phyllis Even, Joint Tenants 

Fjord Capital Partners I, LP 

Fjord Ventures, LLC 
 Fjordinvest,
LLC 
 Fjordinvest (Cayman) Ltd. 

The Stuart and Marianne Foster Trust 

Kieran and Mary Ellen Gallahue Revocable Family Trust 

Gamla Livförsäkringsaktiebolaget Seb Trygg Liv (publ) 

The Huennekens Family Trust dtd 6/14/2007 

James R. Margolis and Marja P. Margolis JTWROS 

Meritech Capital Affiliates IV, L.P. 

Meritech Capital Partners IV, L.P. 

Micro, LLC 
 Gary S. Mocnik
Retirement Trust 
 N5 Investments AS 

NeoMed Innovation V L.P. 
 Hugh
Andrew Neuharth 
 OrbiMed Private Investments IV, LP 

The Board of Trustees of the Leland Stanford Junior University (SBST) 

TIP-Sonendo Limited 
 Andrew Wade

 DNA 07 Limited 
 Timwell
Corporation Limited 
 CVF, LLC 

Fjordinvest (Cayman) II Ltd. 
 JMR
Capital Limited 
 Per Magnus Andersson 

 Security Pacific Finance, Ltd. 

Randy W. Garland, DDS, Inc. Cash Balance Plan &Trust 

Reid V. Pullen, D.D.S., P.C. 

Chad O. Edwards 
 Marcus Palermo

 Pirooz A. Zia 
 General
Atlantic (SOI), L.P. 
 Perceptive Life Sciences Master Fund 

CPV Holdings, LLC 
 PENSCO Trust
Company, Custodian FBO Olav Bergheim IRA. 
 ArrowMark Fundamental Opportunity Fund, LP 

ArrowMark Life Science Fund, LP 

Broadfin Healthcare Master Fund, Ltd. 

EW Healthcare Partners Fund 2, L.P. 

EW Healthcare Partners Fund 2-A, L.P. 

Lookfar Investments, LLC 

Meridian Small Cap Growth Fund 

Redmile Private Investments, II, L.P.EX-4.4

 Exhibit 4.4 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE
SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTION 5.3 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 WARRANT TO PURCHASE STOCK

  

			
	Company:	  	SONENDO, INC. a Delaware corporation
	Number of Shares:	  	15,000
	Type/Series of Stock:	  	Series C-1 Preferred Stock
	Warrant Price:	  	$6.00 per share
	Issue Date:	  	December 31, 2013
	Expiration Date:	  	December 31, 2023
	Credit Facility:	  	This Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Loan and Security Agreement of even date herewith among Oxford Finance LLC, as Lender and Collateral Agent, the Lenders from time
to time party thereto, and the Company (as modified, amended and/or restated from time to time, the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, OXFORD FINANCE LLC
(“Oxford” and, together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”) at the above-stated Warrant
Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. 

SECTION 1. EXERCISE. 

1.1 Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the
Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in
Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being
purchased. 
 1.2 Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner
as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised.
Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

X = Y(A-B)/A 

where: 
  

			
	 X =
	  	the number of Shares to be issued to the Holder;
		
	 Y =
	  	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);
		
	 A =
	  	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and
		
	 B =
	  	the Warrant Price.

  
 1 

 1.3 Fair Market Value. If the Company’s common stock is then traded or quoted
on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the Class is
common stock, the fair market value of a Share shall be the closing price or last sale price of a share of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of
Exercise to the Company. If the Company’s common stock is then traded in a Trading Market and the Class is a series of the Company’s convertible preferred stock, the fair market value of a Share shall be the closing price or last sale
price of a share of the Company’s common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company multiplied by the number of shares of the
Company’s common stock into which a Share is then convertible. If the Company’s common stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good
faith judgment. 
 1.4 Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the
manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of
like tenor representing the Shares not so acquired. 
 1.5 Replacement of Warrant. On receipt of evidence reasonably satisfactory to
the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of
mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount. 

1.6 Treatment of Warrant Upon Acquisition of Company. 

(a) Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity (other than
a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or
reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders beneficially own a
majority of the outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or other transfer by
the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power. 

(b) Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s
stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), either (i) Holder shall exercise this Warrant pursuant to Section 1.1
and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition or (ii) if Holder elects not to exercise the Warrant, this Warrant will expire immediately prior to the
consummation of such Acquisition. 
 (c) The Company shall provide Holder with written notice of its request relating to the Cash/Public
Acquisition (together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public Acquisition giving rise to such notice), which is to be delivered to
Holder not less than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition. In the event the Company does not provide such notice, then if, immediately prior to the Cash/Public Acquisition, the fair market value
of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date, 

  
 2 

 
then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not
previously have been exercised, and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise to the Holder and Holder shall be deemed to have restated each of the representations and
warranties in Section 4 of the Warrant as the date thereof. 
 (d) Upon the closing of any Acquisition other than a Cash/Public
Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the
Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this
Warrant. 
 (e) As used in this Warrant, “Marketable Securities” means securities meeting all of the following
requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its
filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to
exercise this Warrant on or prior to the closing thereof is then traded in a Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling
all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such
restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition. 

SECTION 2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the
Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and
property which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater
number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification
or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

2.2 Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the
Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the
number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the
provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. 

2.3 Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible preferred stock, in the
event that all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Certificate of Incorporation, including, without limitation, in
connection with the Company’s initial, underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the “IPO”), then from and after the date on which all outstanding
shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted had the Shares been outstanding on the date of such conversion, and the
Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have been converted, all subject to further adjustment thereafter from time
to time in accordance with the provisions of this Warrant. 

  
 3 

 2.4 Adjustments for Diluting Issuances. Without duplication of any adjustment
otherwise provided for in this Section 2, the number of shares of common stock issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the manner set forth in the Company’s Certificate of
Incorporation as if the Shares were issued and outstanding on and as of the date of any such required adjustment. 
 2.5 No Fractional
Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the
Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share,
less (ii) the then-effective Warrant Price. 
 2.6 Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant
Price, Class and/or number of Shares, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon
which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares
in effect upon the date of such adjustment. 
 SECTION 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows: 

(a) The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of the
Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $500,000 of such shares were sold. 

(b) All Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares,
shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable
federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock and other securities as
will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into common stock or such other securities. 

(c) The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material respects, as of the Issue
Date. 
 3.2 Notice of Certain Events. If the Company proposes at any time to: 

(a) declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock, or
other securities and whether or not a regular cash dividend; 
 (b) offer for subscription or sale pro rata to the holders of the
outstanding shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights); 

(c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Class; 
 (d) effect an Acquisition or to liquidate, dissolve or wind up; or 

  
 4 

 (e) effect an IPO; 

then, in connection with each such event, the Company shall give Holder: 

(1) at least seven (7) Business Days prior written notice of the date on which a record will be taken for such dividend, distribution, or
subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; 

(2) in the case of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the date
when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange their shares for the securities or other property deliverable upon the occurrence of such event); and

 (3) with respect to the IPO, at least seven (7) Business Days prior written notice of the date on which the Company proposes to file
its registration statement in connection therewith. 
 Reference is made to Section 1.6(c) whereby this Warrant will be deemed to be exercised pursuant
to Section 1.2 hereof if the Company does not give written notice to Holder of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder that is reasonably necessary to enable Holder to
comply with Holder’s accounting or reporting requirements. 
 SECTION 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. 

The Holder represents and warrants to the Company as follows: 

4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired
for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring
this Warrant or the Shares. 
 4.2 Disclosure of Information. Holder is aware of the Company’s business affairs and financial
condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has
had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such
information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3 Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the
Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the
Act. 

  
 5 

 4.5 The Act. Holder understands that this Warrant and the Shares issuable upon
exercise hereof (and the shares of common stock that are issuable upon the conversion of any such Shares or upon the exercise of this Warrant) have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption
depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof (and such shares of common stock) must be held
indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144
promulgated under the Act. 
 4.6 Market Stand-off Agreement. The Holder agrees that the
Shares shall be subject to the Market Standoff provisions in Section 3.9 of that certain Investors’ Rights Agreement, dated as of June 12, 2012, by and among the Company and certain stockholders of the Company (as modified, amended
and/or restated from time to time). 
 4.7 No Stockholder Rights. Except as provided in this Warrant, Holder, as a Holder of this
Warrant, will not have any rights as a stockholder of the Company until the exercise of this Warrant. 
 SECTION 5. MISCELLANEOUS.

 5.1 Term; Automatic Cashless Exercise Upon Expiration. 

(a) Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from
time to time on or before 6:00 PM, Eastern time, on the Expiration Date and shall be void thereafter. 
 (b) Automatic Cashless Exercise
upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in
effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the
Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. 

5.2 Legends. Each certificate evidencing Shares (and each certificate evidencing the securities issued upon conversion of any Shares,
if any) shall be imprinted with a legend in substantially the following form: 
 THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO OXFORD FINANCE LLC DATED
DECEMBER 31, 2013 MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR
OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares
issued upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state
securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company
shall not require Holder to provide an opinion of counsel if the transfer is an affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. 

  
 6 

 5.4 Intentionally Left Blank. 

5.5 Transfer Procedure. After receipt by Oxford of the executed Warrant, Oxford may transfer all or part of this Warrant to one or more
of Oxford’s affiliates (each, an “Oxford Affiliate”), by execution of an Assignment substantially in the form of Appendix 2. Subject to the provisions of Article 5.3 and upon providing the Company with written notice, Oxford,
any such Oxford Affiliate and any subsequent Holder, may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the Shares issuable directly or indirectly, upon conversion of the Shares, if any) to any other
transferee, provided, however, in connection with any such transfer, the Oxford Affiliate(s) or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification
number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable). Notwithstanding any contrary provision herein, at all times prior to the IPO, Holder may not, without the
Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares issued upon any exercise hereof, to any
person or entity who directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor. 

5.6 Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered
and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such
receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or
Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives notice of a change of
address in connection with a transfer or otherwise: 
 Oxford Finance LLC 

133 N. Fairfax Street 

Alexandria, VA 22314 
 Attn:
Legal Department 
 Telephone: [Redacted] 

Facsimile: [Redacted] 
 Email:
[Redacted] 
 Notice to the Company shall be addressed as follows until Holder receives notice of a change in address: 

SONENDO, INC. 
 26051 Merit
Circle, Suite 101 
 Laguna Hills, California 92653 

Attn: Chief Executive Officer 

Fax: [Redacted] 
 Email:
[Redacted] 
 With a copy (which shall not constitute notice) to: 

Reed Smith LLP 
 1901 Avenue of
the Stars, Suite 700 
 Los Angeles, California 90067 

Attn: Michael Sanders, Esq. 

Telephone: [Redacted] 

Facsimile: [Redacted] 
 Email:
[Redacted] 
 5.7 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a
particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

  
 7 

 5.8 Attorneys’ Fees. In the event of any dispute between the parties concerning
the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.9 Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute
one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto. 

5.10 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without
giving effect to its principles regarding conflicts of law. 
 5.11 Headings. The headings in this Warrant are for purposes of
reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 
 5.12 Business Days.
“Business Day” is any day that is not a Saturday, Sunday or a day on which banks in the State of California are closed. 

[Remainder of page left blank intentionally] 

[Signature page follows] 

  
 8 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by
their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	SONENDO, INC.
		
	By:	 	 /s/ Bjarne Bergheim

	Name:	 	Bjarne Bergheim
	Title:	 	President and Chief Executive Officer
	
	“HOLDER”
	
	OXFORD FINANCE LLC
		
	By:	 	 /s/ Hans S. Houser

	Name:	 	 Hans S. Houser

		 	(Print)
	Title:	 	Chief Credit Officer, SVP

 [Signature Page to Warrant to Purchase Stock] 

 APPENDIX 1 

NOTICE OF EXERCISE 
 1.
The undersigned Holder hereby exercises its right purchase                              shares of the
Common/Series                Preferred [circle one] Stock of SONENDO, INC. (the “Company”) in accordance with the attached Warrant To Purchase Stock, and
tenders payment of the aggregate Warrant Price for such shares as follows: 
 [    ] check in the amount of
$                     payable to order of the Company enclosed herewith 

[    ] Wire transfer of immediately available funds to the Company’s account 

[    ] Cashless Exercise pursuant to Section 1.2 of the Warrant 

[    ] Other [Describe]
                                         
                                         
       
 2. Please issue a certificate or certificates representing the Shares in the name specified below:

  

			
		 	  
 Holder’s Name

		 	  

		
		 	  
 (Address)

 3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof. 
  

			
	HOLDER:
	  

		
	By:	 	  

	Name:	 	  

	Title:	 	  

	Date:	 	  

  
 Appendix 1 

 APPENDIX 2 

ASSIGNMENT 
 For
value received, Oxford Finance LLC hereby sells, assigns and transfers unto 
  

					
		 	Name:	  	        OXFORD TRANSFEREE

					
		 	        Address:
                                         
   

					
		 	Tax ID:	  	                                      
                          

 that certain Warrant to Purchase Stock issued by SONENDO, INC. (the “Company”), on December 31, 

2013 (the “Warrant”) together with all rights, title and interest therein. 

 

			
	OXFORD FINANCE LLC
		
	By:	 	  

	Name:	 	  

	Title:	 	  

Date:                         
                                        

By its execution below, and for the benefit of the Company, [OXFORD TRANSFEREE] makes each of the representations and warranties set forth in Article 4 of the
Warrant and agrees to all other provisions of the Warrant as of the date hereof. 
  

			
	[OXFORD TRANSFEREE]
		
	By:	 	  

	Name:	 	  

	Title:	 	                                      
                                         
     ]

  
 Appendix 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]